Webster Equity Partners to Acquire Lifecore Biomedical for Up to…

Event summary

Lifecore Biomedical to be acquired by Webster Equity Partners for up to $663.7M, including contingent value rights (CVRs) of up to $160M.
Common stockholders to receive $6.28 per share in cash at closing, representing a 49.5% premium.
Transaction expected to close in Q4 2026, subject to stockholder and regulatory approvals.
Lifecore's common stock will be delisted from Nasdaq following the transaction.
CVRs tied to revenue and EBITDA performance milestones through 2030.

The big picture

The acquisition of Lifecore Biomedical by Webster Equity Partners highlights the growing interest of private equity firms in contract development and manufacturing organizations (CDMOs) within the biotechnology sector. With a deal size of up to $663.7M, the transaction underscores the strategic value of specialized manufacturing capabilities in the healthcare industry. The inclusion of performance-based CVRs suggests a focus on operational excellence and sustainable profitability, aligning with broader trends of private equity investments targeting mid-term growth opportunities in healthcare services.

What we're watching

Performance Milestones: Whether Lifecore can achieve the revenue and EBITDA targets necessary to trigger the full $160M in CVR payments.
Strategic Fit: How Webster Equity Partners' resources and expertise will accelerate Lifecore's growth and profitability.
Market Reaction: The impact of the delisting and private equity ownership on Lifecore's operational focus and market positioning.